COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH ® (palopegteriparatide; developed as TransCon PTH) is now commercially ...
Ascendis Pharma (ASND) announced that YORVIPATH is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone, administered once-daily ...
Investor's Business Daily on MSN5mon
Ascendis Pharma Zips Higher After FDA Approves Embattled DrugHere's How You Can Play Them. The agency approved Yorvipath, Ascendis Pharma's hypoparathyroid treatment. Hypoparathyroidism ...
JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...
5. Yorvipath (palopegteriparatide) for hypoparathyroidism: Approved Aug. 9, Yorvipath is the first and only medication for hypoparathyroidism in adults, aiming to restore calcium balance.
TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...
CEO Jan Mikkelsen expressed confidence in the company’s growth trajectory, reporting estimated revenues of €202 million for SKYTROFA in 2024, and €29 million for YORVIPATH, with significant ...
COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones.
Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH ...
COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH ® (palopegteriparatide; developed as TransCon PTH) is now commercially ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback